Wire · opportunities
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 October 2026 · Fusion42 review
The FDA granted accelerated approval to dostarlimab for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, based on the AZUR-1 trial where 71% of patients avoided chemotherapy, radiation, and surgery with no disease progression.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
You have a new non-surgical pathway to offer stage II/III MSI-H/dMMR rectal cancer patients, shifting treatment away from chemo and radiation. This move demands quick updates to patient care protocols and follow-up plans with multimodal surveillance.
◆ Coverage
5 sources · 19 Oct 2026
◆ Related on Wire
◆ Topics